Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an update.
Rhythm Biosciences Ltd. has announced the commercial availability of its geneType product and anticipates the launch of ColoSTAT in the second half of 2025. These products, protected by patents, are designed for easy adoption in routine laboratories and represent a significant advancement in cancer risk assessment and detection, potentially impacting the company’s market positioning and offering valuable solutions to stakeholders.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the healthcare industry, focusing on cancer risk evaluation and early detection. The company offers innovative proteomic and genomic technologies, targeting large underserved global markets, and is supported by both public and private healthcare systems.
Average Trading Volume: 230,838
Technical Sentiment Signal: Sell
Current Market Cap: A$16.84M
Learn more about RHY stock on TipRanks’ Stock Analysis page.